Balance Sheet
Accumulated DepreciationAccumulated ExpensesAssetsBuildingsCash & EquivalentsCommon EquityDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReal Estate - GrossReal Estate - NetReceivablesRetained EarningsShareholder's EquityTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Global Medical REIT (GMRE-PB) Liabilities and Shareholders Equity (2016 - 2025)

Global Medical REIT (GMRE-PB) has disclosed Liabilities and Shareholders Equity for 14 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 1.12% year-over-year to $1.2 billion, compared with a TTM value of $5.1 billion through Dec 2025, up 1.57%, and an annual FY2025 reading of $1.2 billion, down 1.12% over the prior year.
  • Liabilities and Shareholders Equity was $1.2 billion for Q4 2025 at Global Medical REIT, down from $1.3 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.4 billion in Q3 2022 and bottomed at $1.1 billion in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $1.3 billion, with a median of $1.3 billion recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity grew 24.15% in 2021, then decreased 9.01% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $1.3 billion in 2021, then rose by 10.27% to $1.4 billion in 2022, then fell by 9.01% to $1.3 billion in 2023, then dropped by 0.88% to $1.3 billion in 2024, then dropped by 1.12% to $1.2 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for GMRE-PB at $1.2 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.3 billion in Q2 2025.